However, HIV advocates told the news outlet they are concerned about the drug’s high cost and potential disparities that could exacerbate racial inequalities in HIV prevention.
Black and Latino gay and bisexual men, who face the highest HIV rates, have historically struggled with low adherence to daily oral prEP, such as Truvada and Descovy.
Despite lenacapavir’s potential, the drug is priced at $3,450 per month, posing a potential barrier for patients. The drug’s manufacturer, Gilead Sciences, is having discussions about pricing, but the cost of widespread domestic access with the medication remains uncertain, according to the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
